L&K BIOMED Co., Ltd.
KKRX:1561007,100.00
KRW
+360.00
(+5.34%)
ISIN
KR7156100000
Return %
Stock
S&P 500
1Y
-21.02
14.39
3Y
0.00
81.42
5Y
-43.07
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Gook-Jin Kang
- Full Time Employees
- 97
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Yongin-si South Korea
- IPO Date
- Nov 30, 2016
- Website
- lnkbiomed.com
- Similar Companies
- Business
- L&K BIOMED Co., Ltd. is a South Korea-based medical device company engaged in the research, development, manufacturing, and commercialization of spinal implants and surgical fixation systems. The company specializes in biomechanical solutions for minimally invasive surgery and open spinal procedures designed to treat degenerative disc disease, spinal stenosis, trauma, deformities, and fractures. Its core product portfolio comprises expandable interbody fusion cages, including the BluEX Lumbar Expandable Cage System across transforaminal, posterior, lateral, anterior, and endoscopic surgical approaches, the BluEX-C height-expandable cervical interbody cage, and the BluEX-LT curved expandable lateral cage; pedicle screw and posterior fixation systems, including the AccelFix-S open screw system and the PathLoc-L minimally invasive system; static interbody fusion cages, including the PathLoc Lumbar Interbody Fusion Cage System; cervical plate and fixation devices, including the CastleLoc-P anterior cervical plate system; sacroiliac joint fusion implants; and thoracic pectus deformity correction devices. Founded in 2008 and headquartered in Yongin-si, Gyeonggi-do, South Korea, with additional corporate and clinical research facilities in Seoul, L&K BIOMED distributes its medical devices globally across North America, Europe, Asia, and other international territories, operating in the United States primarily through its subsidiary, Aegis Spine, Inc. (Aegis Meditech, Inc.). In recent developments, the company received U.S. Food and Drug Administration (FDA) 510(k) clearances for its BluEX Lumbar Expandable Cage System in October 2024, the PathLoc Lumbar Interbody Fusion Cage System in July 2025, and the BluEX-C expandable cervical cage in May 2026, followed by expanded footprint dimensional approvals in August 2026. In June 2026, the company completed its first-in-human clinical implantation of the BluEX-LT expandable lateral cage at WakeMed Health & Hospitals in the United States. In September 2026, L&K BIOMED formed a strategic product development partnership with spine specialist Dr. K. Daniel Liu to design next-generation cervical implants. These advancements follow the resolution of legacy intellectual property litigation in the United States in late 2023 and support ongoing capital investments into expanded manufacturing facilities and direct hospital distribution channels across North America.